MXCT / MaxCyte lifts guidance again as cell therapy demand continues to grow

MaxCyte focuses on cell-engineering platform technology. The company blamed lower orders for a likely revenue decline in the third quarter. more_horizontal

MaxCyte (NASDAQ: MXCT ) stock is sliding lower on Thursday following the release of preliminary earnings data for Q3. The bad news for investors in M more_horizontal

MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sean Menarguez - Head-IR Doug Doerfler - more_horizontal

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per s more_horizontal

ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing ena more_horizontal

MaxCyte, Inc. (NASDAQ:MXCT ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Doug more_horizontal

MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement am more_horizontal

MaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive more_horizontal